Bevacizumab (anti-VEGF)

货号 (SKU)	包装规格	是否现货
B411998-1mg	1mg	现货
B411998-5mg	5mg	现货
B411998-10mg	10mg	期货

基本描述

规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
英文名称	Bevacizumab (anti-VEGF)
别名	贝伐珠单抗; 贝伐单抗; Recombinant Bevacizumab Antibody; rhuMab VEGF; Avastin; Anti-Human VEGF; Humanized Antibody; Bevacizumab (Anti-Human VEGF, Humanized Antibody); Bevacizumab; EC 2.7.10.1 antibody; FLT 1 antibody; FLT antibody; Flt-1 antibody; FLT1 antibody; Fm
英文别名	Recombinant Bevacizumab Antibody; rhuMab VEGF; Avastin; Anti-Human VEGF; Humanized Antibody; Bevacizumab (Anti-Human VEGF, Humanized Antibody); Bevacizumab; EC 2.7.10.1 antibody; FLT 1 antibody; FLT antibody; Flt-1 antibody; FLT1 antibody; Fms like tyrosi
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
来源	CHO supernatant
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
产品介绍	Bevacizumab 是一种人源化的anti-VEGF单克隆抗体，是VEGF的抑制剂。可与所有人源VEGF-A亚型（和具有生物活性的蛋白水解片段）结合、中和。 Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg

名称和标识符

分子式
分子量	149 kDa(Average)

数据库链接

PubChem SID	178103377
IMGT/mAb-DB	24
Wikipedia	Bevacizumab
Reactome Reaction	R-HSA-9679477
Reactome Drug	R-ALL-9679458

化学和物理性质

稳定性与储存	Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.

关联配体

Ligand ID

6771

名称

bevacizumab

别名

Avastin®

类别

Antibody

学名

4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide

生物活性评价

The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).

评价

Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars: Amgen's bevacizumab-awwb (Mvasi®) was the first bevacizumab biosimilar to be FDA approved. This and others are listed in the table below.

Name	Trade name	Company	Clinical Phase	Indications
bevacizumab-awwb	Mvasi	Amgen	Approved (FDA 2017)	Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
bevacizumab-bvzr; PF-06439535	Zirabev	Pfizer	Approved (EMA & FDA 2019)	Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney, cervical and breast cancers, plus recurrent glioblastoma (FDA).
SB8	Aybintio	Samsung Bioepis	Approved (EMA 2020)	Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
FKB238	Equidacent	Centus Biotherapeutics	Approved (EMA 2020)	Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
bevacizumab; MYL-1402O	Abevmy	Mylan	Approved (EMA 2021)	As per originator reference product.
bevacizumab	Alymsys	Mabxience Research/Zentiva	Approved (EMA 2021)	As per originator reference product.
bevacizumab-maly; BEVZ92-MB02	Oyavas; Alymsys	STADA Arzneimittel; Amneal Pharmaceuticals	Approved (EMA 2021; FDA 2022)	As per originator reference product: NOT adjuvant treatment of colon cancer
bevacizumab	Onbevzi	Samsung Bioepis/Biogen	Approved (EMA 2021)	As per originator reference product
bevacizumab-adcd; CT-P16	Vegzelma	Celltrion	Approved (EMA & FDA 2022)	Approved to treat a range of advanced solid tumours in combination with other cancer drugs: Colorectal, breast, ovarian, fallopian tube, peritoneal, and uterine neoplasms, non-small cell lung cancer, and renal cell carcinoma
CBT124		Cipla BioTech	Phase 3

单字母多肽序列

三字母多肽序列

翻译后修饰

化学修饰

临床描述

This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression within 6 months of platinum therapy. All patients will receive standard chemotherapy with either paclitaxel or topotecan or liposomal doxorubicin. Patients randomized to Arm 2 of the study will receive Avastin (10 mg/kg iv 2-weekly or 15 mg/kg iv 3-weekly) concomitantly. Anticipated time on study treatment is until disease progression. Patients will then receive standard of care, those in Arm 1 (chemotherapy only) may opt to receive Avastin (15 mg/kg iv 3-weekly). Target sample size is 100-500 individuals.
- The study is evaluating the safety and tolerability of Nivolumab (BMS-936558) when combined with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine; Cisplatin/Pemetrexed; and Carboplatin/Paclitaxel) in subjects with NSCLC. - The study is evaluating the safety and tolerability of Nivolumab as maintenance therapy in combination with Bevacizumab/Avastin that will be given after at least 4 cycles of platinum doublet chemotherapy. - The study is evaluating the safety and tolerability of Nivolumab in combination with Erlotinib among epidermal growth factor receptor (EGFR) mutation positive non-squamous NSCLC subjects and as monotherapy in subjects with NSCLC. - The study is evaluating the safety and tolerability of Nivolumab in combination with Ipilimumab in subjects with squamous and non-squamous NSCLC. - The study is evaluating the safety and tolerability of Nivolumab as switch maintenance therapy in subjects with squamous and non-squamous NSCLC. - The study is evaluating the safety and tolerability of Nivolumab as monotherapy among subjects with untreated, asymptomatic brain metastases and no evidence of cerebral edema.
This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
The novel identified coronavirus (SARS-CoV-2) in 2019 causes an nationwide outbreak as well as public health crisis in China, and expands globally. Pulmonary edema is one of the most detrimental symptoms and usually presents in severe and critical coronavirus disease (COVID-19), resulting in dyspnea, acute lung injury (ALI) ,acute respiratory distress syndrome (ARDS), and even death. Recent evidence revealed higher levels of blood Vascular Endothelial Growth Factor (VEGF) in COVID-19 patients compared with healthy controls. VEGF is considered as the most potent vascular permeability inducers. Numerous studies have revealed that VEGF was a key factor and a potential therapeutic target in ALI and ARDS. Bevacizumab, an anti-VEGF drug, approved by the FDA on February 26, 2004 and widely used in clinical oncotherapy, is a promising drug for ALI/ARDS in COVID-19 through suppression of pulmonary edema.
Bevacizumab, ZERIBEV? (Pfizer)/AVASTIN? (Roche) 25 mg/ml ?, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU. This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN?/ ZERIBEV? (bevacizumab) COVID-19 patients hospitalized in conventional units. This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of AVASTIN?/ ZERIBEV? (bevacizumab) alone versus standard of care (SoC) in patients hospitalized in conventional units.
The novel coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019, which causes epidemic worldwide. Novel coronavirus disease (COVID-19) causes acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) in the severe and critically severe patients. Pulmonary edema is the key detrimental feature of ALI/ARDS. Autopsy of patients died from COVID-19 reported that, pulmonary mucus exudation was severe, more obvious than SARS infection. Pulmonary CT scanning and pathological findings also suggest that pulmonary edema caused by inflammatory exudation is a distinguished feature of COVID-19. However, specific pharmacotherapy is lacking.Vascular endothelial growth factor (VEGF) is known as the most potent inducing factors to increase vascular permeability. Bevacizumab is an anti VEGF recombinant humanized monoclonal antibody, which has been used in anti-tumor treatment for 16 years. Evidence suggest that Bevacizumab is a promising drug for severe and critical COVID-19 patients.

来源公司

Hoffmann-La Roche
Bristol-Myers Squibb
National Cancer Institute (NCI)
Amgen
Qilu Hospital of Shandong University
Assistance Publique - H?pitaux de Paris
Qilu Hospital of Shandong University

参考文献

1. Glade-Bender J, Kandel JJ, Yamashiro DJ. (2003) VEGF blocking therapy in the treatment of cancer.. Expert Opin Biol Ther, 3 (2): (263-76). [PMID:12662141]
2. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.. N Engl J Med, 349 (5): (427-34). [PMID:12890841]
3. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. (2016) Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.. Ann Oncol, 27 (1): (114-21). [PMID:26487588]

图片

ELISA: Bevacizumab (anti-VEGF) (B411998)

Bevacizumab (anti-VEGF) (B411998) - ELISA
Immobilized Recombinant Human VEGF Protein (rp155965) at 1 μg/mL can bind Bevacizumab (anti-VEGF) (B411998) with the EC50 of 4.16 ng/mL.

SEC: Bevacizumab (anti-VEGF) (B411998)

Bevacizumab (anti-VEGF) (B411998) - SEC
The purity of Bevacizumab (anti-VEGF) (B411998) is more than 95% verified by HPLC.

产品问答

登录提交问题

查看全部

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

Bevacizumab (anti-VEGF)

库存信息

库存信息

库存信息

基本描述

名称和标识符

数据库链接

化学和物理性质

关联配体

参考文献

图片

相关文档

质检报告COA

产品问答

产品问答

91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

91高清自产国产拍,无码免费A级毛片大全,日本 欧美 国产中文字幕,99re热视频这里只有精品视频首页

Bevacizumab (anti-VEGF)

库存信息

库存信息

库存信息

基本描述

名称和标识符

数据库链接

化学和物理性质

关联配体

参考文献

图片

相关文档

质检报告COA

产品问答

产品问答

91高清自产国产拍,无码免费A级毛片大全,日本 欧美 国产中文字幕,99re热视频这里只有精品视频首页

91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页